Janssen and Sanofi enter agreement for potential vaccine programme

Betsy Goodfellow | October 5, 2023 | News story | Business Services Immunology, Janssen, Sanofi, e coli, vaccines 

Janssen Pharmaceuticals, a Johnson & Johnson company, has announced a development and commercialisation agreement with Sanofi for Janssen’s extraintestinal pathogenic Escherichia coli (ExPEC) investigational vaccine programme.

The lead vaccine candidate is currently being assessed in the phase 3 E.mbrace study, evaluating the vaccine for the prevention of invasive E. coli disease (IED) in adults over the age of 60.

The agreement is still subject to certain customary closing conditions.

Advertisement

The collaboration is intended to combine the research and development strengths of Janssen with Sanofi’s global commercial vaccine expertise to advance the ExPEC programme.

The two companies will co-fund current and future research and development costs, though Sanofi will pay Janssen an upfront payment of $175m followed by various milestone payments.

Penny Heaton, MD, global therapeutic area head of Infectious Diseases and Vaccines at Janssen Research and Development, commented: “We’re committed to addressing the unmet need for a vaccine to protect against IED, which affects nearly ten million adults each year, has only limited therapeutic options available and can cause life-threatening infections. This agreement will enable us to accelerate the development and potential commercialisation of this important preventive option.”

Betsy Goodfellow

Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria

Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition

The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …

sanofi

Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline

Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …

The Gateway to Local Adoption Series

Latest content